C4 Therapeutics Inc (NASDAQ: CCCC) on Monday, plunged -6.27% from the previous trading day, before settling in for the closing price of $2.71. Within the past 52 weeks, CCCC’s price has moved between $1.09 and $5.10.
A company in the Healthcare sector has dropped its sales by -8.92% annually for the last half of the decade. The company achieved an average annual earnings per share of 2.75%. With a float of $77.61 million, this company’s outstanding shares have now reached $96.91 million.
In an organization with 110 employees, it is important to assess its efficiency.
C4 Therapeutics Inc (CCCC) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of C4 Therapeutics Inc is 19.92%, while institutional ownership is 57.44%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.49 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.45) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.75% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
C4 Therapeutics Inc (CCCC) is currently performing well based on its current performance indicators. A quick ratio of 5.76 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.67, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -1.38 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Let’s dig in a bit further. During the last 5-days, its volume was 1.11 million. That was inferior than the volume of 1.57 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 79.51%.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 35.84%, which indicates a significant decrease from 54.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.15 in the past 14 days, which was lower than the 0.23 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.40, while its 200-day Moving Average is $2.10. However, in the short run, C4 Therapeutics Inc’s stock first resistance to watch stands at $2.63. Second resistance stands at $2.71. The third major resistance level sits at $2.77. If the price goes on to break the first support level at $2.48, it is likely to go to the next support level at $2.42. Assuming the price breaks the second support level, the third support level stands at $2.34.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
Market capitalization of the company is 246.16 million based on 96,914K outstanding shares. Right now, sales total 35,580 K and income totals -105,320 K. The company made 11,230 K in profit during its latest quarter, and -32,170 K in sales during its previous quarter.
